Amelioration of liver and kidney function parameters in alloxan-induced diabetic rats treated with 3-[2-(1,5-Dimethyl-3-oxo-2-Phenyl-2,3-Dihydro-1H-Pyrazol-4-yl) Hydrazinylidene]-1-Phenylbutanedione, and its Ni(II) Complex.

Abstract

This hydrazone: 3-[2-(1,5-Dimethyl-3-oxo-2-Phenyl-2,3-Dihydro-1H-Pyrazol-4-yl) Hydrazinylidene]-1-Phenylbutanedione (HL), and its Ni (II) Complex ([Ni(HL)2]Cl2) have been reported to possess hypoglycaemic property but the effects of their use on kidney and liver functions in diabetic animals have not been investigated. The study investigated some biochemical parameters in the liver and kidney of alloxan-induced diabetic rats treated with these hydrazone compounds. Diabetes was induced by a single intraperitoneal dose of alloxan (150 mg/kg). Data showed that these compounds induced a significant decrease in serum glucose levels in the diabetic rats. Diabetic rats were administered orally with compounds for fourteen days after which some biochemical indices in the serum, liver and kidney were measured and compared with the control. Serum alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea, total protein and creatinine of untreated diabetic group was significantly elevated when compared with the normal control group. The ALP, AST concentrations of diabetic rats treated with low and high doses of HL was observed to be non-significantly (p > 0.05) higher compared with rats in the normal control group A. A significantly (p < 0.05) decrease in the ALT, AST and ALP concentrations of diabetic rats treated with 200 and 400 mg/kg b.w. of HL and [Ni(HL)₂]Cl₂ were observed when compared with untreated rats in group B. These results suggest that administration of these compounds to diabetic rats did not have any adverse effect on the liver and kidney functions in rats showing that the compounds are not toxic to man.